51 results about "Human Parainfluenza Virus" patented technology

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

Recombinant human parainfluenza virus type 1 (HPIV1) compostions, formulations and methods are provided. The recombinant HPIV1 viruses and HPIV1 chimeric and chimeric vector viruses provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic composition s for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV1 genome or antigenome.

The invention discloses a nucleic acid combined testing kit of respiratory tract infection pathogens. The invention develops a set of primer-probe combinations which can detect multiple types of respiratory tract infection pathogens such as novel coronavirus, influenza virus a, influenza virus b, respiratory syncytial virus, human parainfluenza virus, adenovirus, mycoplasma pneumonia and chlamydiapneumonia through combination of a multiple fluorescence quantitative PCR technology and a flow-through hybridization and gene chip technology, wherein nucleotide sequences thereof are shown by SEQ ID NO:1-36 respectively. The nucleic acid combined testing kit of the respiratory tract infection pathogens is established. The kid can realize synchronous combined testing of the 8 respiratory tract infection pathogens, is high in detection accuracy, specificity and sensitivity, good in repeatability, low in false negativity and false positivity, short in detection time and low in cost, can realize comprehensive detection of a patient, can locate a disease source accurately, can realize treatment in time or make corresponding quarantine measures and is of important significance to effective control of respiratory tract infection and subsequent prevention of outbreak of relevant contagion and infection.

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The invention discloses a respiratory tract infection pathogen nucleic acid combined detection kit. The invention develops a primer and probe combination for detecting various respiratory tract infection pathogens such as novel corona virus, influenza A virus, influenza B virus, respiratory syncytial virus, human parainfluenza virus, adenovirus, mycoplasma pneumoniae and chlamydia pneumoniae by combining a multiple fluorescent quantitative PCR technology and a diversion hybridization gene chip technology. The nucleotide sequences of the primer and probe combination are shown in SEQ ID NO: 1-36in sequence. The respiratory tract infection pathogen nucleic acid combined detection kit is constructed. Synchronous joint detection of eight respiratory tract infection pathogens can be realized, the detection accuracy is good, the specificity is strong, the sensitivity is high, the repeatability is good, false negative and false positive are low, the detection time is short, the cost is low, apatient can be comprehensively detected, the pathogens can be accurately positioned, timely treatment is carried out or corresponding isolation measures are carried out, and the kit has important significance for effectively controlling respiratory tract infection to prevent related infectious infection outbreak.

The invention belongs to the technical field of virus detection kit, and provides a human parainfluenza virus I, II, III, and IV-type quadruple-PCR detection kit, and a detection method thereof. The human parainfluenza virus I, II, III, and IV-type quadruple-PCR detection kit comprises human parainfluenza virus specific primers and gene probes; and in the detection method, the human parainfluenza virus I, II, III, and IV-type quadruple-PCR detection kit is used for detection. Compared with the prior art, the human parainfluenza virus I, II, III, and IV-type quadruple-PCR detection kit and the detection method possess following advantages: detection of human parainfluenza virus I, II, III, and IV types can be realized at the same time; sensitivity, specificity, and accuracy are high; and detection period is short.

The invention discloses a real-time fluorescent quantitative PCR probe primer group and a kit for rapid and qualitative typing detection of four types of human parainfluenza viruses. The kit comprises the probe primer group specially designed for the four types of human parainfluenza viruses, i.e., HPIV-1, HPIV-2, HPIV-3 and HPIV-4; primer sequences in the probe primer group are as shown in SEQ ID NO.1-27; and probe sequences in the probe primer group are as shown in SEQ ID NO. 28 to 38. According to the invention, a reaction system of the real-time fluorescent quantitative PCR kit for rapid qualitative typing detection of the four types of human parainfluenza viruses aims at conserved regions of genomes of the four types of human parainfluenza viruses and can be used for rapid detection of parainfluenza viruses in nasopharynx swabs or sputum samples, and detection results can be used for auxiliary diagnosis of symptoms such as cough, fever, pneumonia and the like causedby parainfluenza and rapidly distinguishing parainfluenza patients from other fever and pneumonia patients.

This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial vims (RSV), human parainfluenza virus (HPV), measles virus (MeV). and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The present invention relates to isolated, attenuated viral strains of human parainfluenza virus 2 (HPIV-2), which are useful in live vaccine preparations. These strains exhibit a temperature sensitive and cold adapted phenotype useful for stimulating a protective immune response in an inoculated mammal without producing severe symptoms.

The invention discloses a kit for simultaneously detecting nucleic acids of seven respiratory pathogens and an application thereof. The kit is based on double amplification (RNA constant temperature amplification + multi-biotin signal amplification) technology, involving H1N1 / H3N2 type of influenza A virus, influenza B virus, respiratory syncytial virus, human parainfluenza virus 1 / Type 2 / 3, B / E genus of adenovirus, Mycoplasma pneumoniae, Chlamydia pneumoniae. The invention does not need RNA extraction, is not easy to be polluted in the detection, has high sensitivity and strong specificity, and can be widely used in the detection of these seven respiratory pathogen nucleic acids.

The invention provides self replicating infectious recombinant paramyxoviruses. The recombinant paramyxovirus preferably have one or more attenuating mutations. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein. In some embodiments, recombinant paramyxovirus have at least one temperature sensitive mutation and one non-temperature sensitive mutation. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.